Joanna Udo de Haes

Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence

Deepak Cyril D’Souza, Nagendra M. Singh, Jacqueline Elander et al. · Neuropsychopharmacology · 2011 · 63 citations · Full text

Medicine, Neuroscience, Pharmacology +15

5-Hydroxytryptamine1A Receptor Occupancy by Novel Full Antagonist 2-[4-[4-(7-Chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2 H)-one-1,1-dioxide: A [11C][O-methyl-3 H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide Trihydrochloride (WAY-100635) Positron Emission Tomography Study in Humans

Eugenii A. Rabiner, Martin R. Wilkins, Federico Turkheimer et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 44 citations

Medicine, Medicinal Chemistry, Pharmacology +11

Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment

K. Chris Min, Kenneth C. Lasseter, Thomas Marbury et al. · International Journal of Clinical Pharmacology and Therapeutics · 2017 · 27 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Early stage development of the glycine‐1 re‐uptake inhibitor <scp>SCH</scp> 900435: central nervous system effects compared with placebo in healthy men

M Liem-Moolenaar, Pierre Peeters, Ingrid M. C. Kamerling et al. · British Journal of Clinical Pharmacology · 2012 · 10 citations

Medicine, Pharmacology, Psychiatry +17

LO7 : A single subcutaneous dose of 2mg/kg or 4mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against MIR-122, results in significant viral load reductions in chronic hepatitis C patients

MH Van Der Ree, M. L. Vree, F. Stelma et al. · Journal of Hepatology · 2015 · 10 citations

Pharmacy, Pharmacology, Pharmacotherapy +14